PMID- 36110538
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220917
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Antidepressant-like activity, active components and related mechanism of 
      Hemerocallis citrina Baroni extracts.
PG  - 967670
LID - 10.3389/fphar.2022.967670 [doi]
LID - 967670
AB  - Hemerocallis citrina Baroni [Asphodelaceae], which is traditional herbal 
      medicine, has been widely used for treating depressive disorders in Eastern-Asia 
      countries. However, the active compounds and corresponding mechanism of 
      anti-depression are not yet completely clarified. In this study, the 
      anti-depressive activities of six H. citrina extracts were primarily evaluated. 
      The results showed that the water extract of H. citrina flowers (HCW) displays 
      significant anti-depressive activity. A total of 32 metabolites were identified 
      from HCW by high-performance liquid chromatography/quadrupole time-of-flight mass 
      spectrometry (HPLC-Q-TOF-MS) and nuclear magnetic resonance (NMR). And then, the 
      anti-depressive activity of the high-level compound (rutin) in HCW was also 
      estimated. The results indicated that rutin displayed significant anti-depressive 
      activity and was one of the main active ingredients. Finally, the anti-depressive 
      mechanisms of HCW and rutin were investigated based on the intestinal 
      microorganisms. The results showed that HCW and rutin increase the diversity and 
      richness of the intestinal flora and regulate the specific intestinal 
      microorganisms such as Bacteroides and Desulfovibrio genera in depressed mice. 
      This work marks the first comprehensive study of the active components, 
      anti-depressive activities and corresponding mechanisms of different H. citrina 
      extracts, which provide a potential possibility for developing new 
      antidepressants.
CI  - Copyright (c) 2022 Liu, Ye, Yang, Zhong, He, Xu, Fang, Deng, Xu, Zeng and Qing.
FAU - Liu, Jinghong
AU  - Liu J
AD  - College of Horticulture, Hunan Agricultural University, Changsha, China.
AD  - Green Melody Bioengineering Group Company Limited, Changsha, China.
FAU - Ye, Tian
AU  - Ye T
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
FAU - Yang, Shuaiyong
AU  - Yang S
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
FAU - Zhong, Xiaohong
AU  - Zhong X
AD  - College of Horticulture, Hunan Agricultural University, Changsha, China.
FAU - He, Wei
AU  - He W
AD  - Green Melody Bioengineering Group Company Limited, Changsha, China.
FAU - Xu, Mengtao
AU  - Xu M
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
FAU - Fang, Jinpeng
AU  - Fang J
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
FAU - Deng, Miao
AU  - Deng M
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
FAU - Xu, Ning
AU  - Xu N
AD  - College of Horticulture, Hunan Agricultural University, Changsha, China.
FAU - Zeng, Jianguo
AU  - Zeng J
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
AD  - Datong Daylily Industrial Development Research Institute, Datong, China.
FAU - Qing, Zhixing
AU  - Qing Z
AD  - College of Food Science and Technology, Hunan Agricultural University, Changsha, 
      China.
AD  - Datong Daylily Industrial Development Research Institute, Datong, China.
LA  - eng
PT  - Journal Article
DEP - 20220829
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9469015
OTO - NOTNLM
OT  - CUMS mice
OT  - HPLC-Q-TOF-MS
OT  - antidepressant-like effect
OT  - chemical constituents
OT  - hemerocallis citrina baroni [asphodelaceae]
OT  - intestinal flora
COIS- Author WH was employed by the Green Melody Bioengineering Group Company. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/17 06:00
MHDA- 2022/09/17 06:01
PMCR- 2022/08/29
CRDT- 2022/09/16 02:35
PHST- 2022/06/13 00:00 [received]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/09/16 02:35 [entrez]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/09/17 06:01 [medline]
PHST- 2022/08/29 00:00 [pmc-release]
AID - 967670 [pii]
AID - 10.3389/fphar.2022.967670 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Aug 29;13:967670. doi: 10.3389/fphar.2022.967670. 
      eCollection 2022.